That’s why, in late 2023 we embarked on an ambitious policy development programme, giving a voice to the millions of patients and thousands of ...

Postsurgical Keytruda (pembrolizumab) tended to lengthen the time patients lived without relapse or complications from their cancer — a statistic known as ...

Patients with previously untreated locally advanced or metastatic urothelial carcinoma experienced favorable progression-free survival (PFS; the time a ...

Patients with metastatic castration-resistant prostate cancer who underwent prior treatment with external beam radiation therapy (EBRT) and were treated ...

My daughters didn’t know about the wild goose chase leading up to biopsies of the tumors in each of my lungs.For years I held onto authenticity as a ...

Patients with advanced urothelial carcinoma, a type of bladder cancer, some of whom were ineligible for cisplatin, who were treated with frontline Keytruda ...

Adding Nubeqa (darolutamide) to docetaxel and androgen deprivation therapy (ADT) lowered hospitalization rates for metastatic hormone-sensitive prostate ...

Patients with bladder cancer who are being treated with the immunotherapy agent, Keytruda (pembrolizumab) should always reach out to their oncology team if ...

Since 2020, rates of HRRm testing have been increasing over time, after the initial FDA approval of Lynparza, a PARP inhibitor.Personalized treatment ...

Patients with prostate cancer showed improvements after receiving Zytiga (abiraterone acetate), prednisone and Erleada (apalutamide) with another therapy, ...